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Abstract
Background: To examine the outcomes of highly-active antiretroviral therapy (HAART) for individuals with free access 
to healthcare, we evaluated 2327 patients in a cohort study composed of military personnel and beneficiaries with HIV 
infection who initiated HAART from 1996 to the end of 2007.
Methods: Outcomes analyzed were virologic suppression (VS) and failure (VF), CD4 count changes, AIDS and death. VF 
was defined as never suppressing or having at least one rebound event. Multivariate (MV) analyses stratified by the 
HAART initiation year (before or after 2000) were performed to identify risk factors associated with these outcomes.
Results: Among patients who started HAART after 2000, 81% had VS at 1 year (N = 1,759), 85% at 5 years (N = 1,061), 
and 82% at 8 years (N = 735). Five years post-HAART, the median CD4 increase was 247 cells/ml and 34% experienced 
VF. AIDS and mortality rates at 5 years were 2% and 0.3%, respectively. In a MV model adjusted for known risk factors 
associated with treatment response, being on active duty (versus retired) at HAART initiation was associated with a 
decreased risk of AIDS (HR = 0.6, 95% CI 0.4-1.0) and mortality (0.6, 0.3-0.9), an increased probability of CD4 increase ≥ 
50% (1.2, 1.0-1.4), but was not significant for VF.
Conclusions: In this observational cohort, VS rates approach those described in clinical trials. Initiating HAART on 
active duty was associated with even better outcomes. These findings support the notion that free access to 
healthcare likely improves the response to HAART thereby reducing HIV-related morbidity and mortality.
Background
Despite substantial progress since the introduction of
highly-active antiretroviral therapy (HAART) [1-4],
maintaining virologic suppression is predominantly chal-
lenged by suboptimal antiretroviral (ARV) adherence.
Studies have shown that difficulty with adherence is usu-
ally associated with (1) significant barriers to care, (2)
ARV intolerability and (3) individual factors such as edu-
cation, treatment fatigue, and the psychosocial context of
the patient [5-7].
We sought to examine a large, multicenter cohort com-
posed of military personnel and beneficiaries with HIV
infection followed since diagnosis in order to illustrate
the HAART outcomes for patients within a free-access
healthcare system in the United States. The U.S. military
medical system provides comprehensive HIV education,
care and treatment, including the provision of ARVs and
regular visits with HIV clinicians at medical treatment
facilities (MTF), at no cost to the patient. Mandatory
periodic HIV screening according to Department of
Defense (DoD) policy [8] allows treatment initiation to be
considered at an early stage of infection. Active duty per-
sonnel are required to attend the MTF at least twice
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yearly for formal medical evaluations. Following retire-
ment from active duty, or separation for medical disabil-
ity, all individuals retain health benefits and may continue
participation in the cohort study while receiving their pri-
mary HIV care either within or outside of the military
healthcare system.
Aside from the advantages afforded by the medical sys-
tem, there are aspects of this cohort that allow for a
unique perspective on HIV treatment response. The mili-
tary population from which these patients are derived
consists of highly motivated and disciplined individuals
who possess either a minimum of a high school equiva-
lent education (enlisted) or an undergraduate college
degree (officers) and maintain rigorous physical stan-
dards [9-11]. As a consequence of periodic random drug
screening, the reported rate of injection drug use (IDU)
in this population is less than one percent [12]. Thus,
many of the factors which typically hinder the clinical
r espon se  t o HAAR T  in m os t  Nort h Am erican c ohorts
[13-15], such as IDU, homelessness and unemployment,
are minimized or eliminated in the military setting. Addi-
tionally, the cohort is racially balanced and geographically
diverse reflecting the distribution of individuals with HIV
in the U.S.[16]. As a separate aim, this cohort provided an
opportunity to examine the relationship between demo-
graphic (e.g. race/ethnicity) and clinical factors (hepatitis
B, prior STI, etc.) with outcomes after HAART in a U.S.




The U.S. Military HIV Natural History Study (NHS) is a
prospective multicenter observational study of HIV-
infected active duty military personnel and other benefi-
ciaries (spouses, dependents, and retired military person-
nel) from the Army, Navy/Marines and Air Force. All
participants provided written informed consent. The
cohort characteristics have been previously described
[17]. Patients were included in this analysis if they were
enrolled in the NHS and initiated HAART at any time
from 1996 until December 31, 2007 with data collected
through July 1, 2008. The NHS has been approved by the
Institutional Review Board of each participating center.
Definitions
S e r o c o n v e r t e r s  ( S C )  w e r e  d e f i n e d  a s  p a t i e n t s  h a v i n g  a
documented HIV seronegative date prior to the first pos-
itive HIV date. The estimated date of seroconversion for
SC was defined as the midpoint between the two dates.
All CD4 count and VL measurements were done as part
of routine clinical care. The clinically-approved method-
ology for this testing varied by site and over time. Sexu-
ally transmitted infections (STIs) were defined as having
a documented clinical history of gonorrhea, chlamydia,
syphilis or herpes simplex at any time prior to initiation
of HAART. Chronic hepatitis B co-infection was defined
as having at least two positive hepatitis B surface antigen
tests at least 6 months apart. Hepatitis C virus (HCV) co-
infection was defined as having at least one positive HCV
antibody test. ARV use referred to any antiretroviral ther-
apy not meeting the NHS definition of HAART [17].
HAART initiation was the date when HAART was first
prescribed. AIDS-defining illnesses were defined using
the 1993 CDC classification but did not include CD4
count < 200 as an endpoint [18].
Statistical Analysis
Outcomes were described for all patients and separately
for those initiating HAART from 1996-1999 (early
HAART era, EHE) and for those starting HAART in
2000-2007 (late HAART era, LHE). Virologic outcomes
and CD4 cell count response were described at 6-month
intervals through 8 years after the initiation of HAART.
Due to differing lengths of follow-up after HAART initia-
tion, the sample size was 1063 (46%) at 5 years and 735
(32%) at 8 years. CD4 and viral load (VL) at HAART were
the last recorded value up to 6-months before HAART.
Six-month follow-up values where those recorded closest
to the 6-month interval after HAART initiation (within a
window of ± 3 months). Patients with missing laboratory
values for a given time point were excluded from analyses
at that time point. Virologic suppression (VS) was
defined as an undetectable viral load (< 400 copies/mL).
Virologic failure (VF) was defined as 2 consecutive VL
detectable after VS (virologic rebound) or never achiev-
ing VS (never suppressed). Always suppressed was
defined as having all measured VL undetectable for the
entire period beginning 6 months after HAART initia-
tion. CD4 count outcomes were expressed as the group
mean and the mean increase after HAART initiation at a
given time point. The percentage of patients who experi-
enced at least a 30% or 50% CD4 count increase from
HAART initiation was also determined. Switches and dis-
continuations of ARVs were not counted as failures.
Kaplan Meier (KM) life-table methods were used to
estimate the cumulative rate of VF, CD4 increase of 50%,
AIDS-defining conditions, and all-cause mortality.
Patients without the event of interest were censored at
the last recorded visit. For time-to-VF, patients never
suppressed were considered to have failed at time zero.
Stratified Cox-regression (by HAART initiation era and
medical center) was used to determine the association of
relevant covariates with these same outcomes. Baseline
covariates used in the model were those found to be asso-
cia t ed ( p < 0. 1)  i n u nivaria t e  a na lyses  as  we ll  as  t hose
shown to be risk factors in the literature.Marconi et al. AIDS Research and Therapy 2010, 7:14
http://www.aidsrestherapy.com/content/7/1/14
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Results
Baseline Characteristics
Characteristics for patients who initiated HAART overall
and by HAART initiation era are shown in Table 1. A
total of 2,327 patients initiated HAART; 1,631 during the
EHE and 696 during the LHE. Average follow-up after
initiation of HAART was 6.2 years for all patients, 7.4
years in the EHE and 3.4 years in the LHE. The mean age
at HAART start was 35 years overall and 9.5% were
women. The race/ethnicity distribution was equally
divided between African and European Americans (44%
each); 8% were Hispanic and 4% were of other race/eth-
nicities. Overall, 213 (9.9%) were commissioned or war-
rant officers at study enrollment; 56% were active duty at
time of HAART . The mean CD4 level at HAART start
was 343 cells/mL and was similar in both eras. Patients in
the LHE were more likely to be active duty, have a shorter
duration between HIV diagnosis and HAART initiation,
and less likely to have an AIDS-defining illness prior to
HAART initiation, than those in the EHE.
Antiretroviral Use
As expected, both prior ARV use and initial HAART reg-
imen differed significantly (p < 0.001) between eras
(T able 1, Figure 1A). Nearly 69% of patients in the EHE
had prior ARV use compared to 15% in the LHE (p <
0.001). In the EHE, 85% used a PI-containing (77%
unboosted) initial HAART regimen whereas in the LHE,
65% used an NNRTI-containing initial regimen (predom-
inantly efavirenz). Of the 2,327 patients initiating their
first HAART regimen, 557 (24%) remained on the same
regimen for the entire duration of follow up; 53.5% were
on their initial regimen at one-year (Figure 1B). At the
end of follow-up, 84% were still on HAART. Of those still
on HAART, 23% were on an unboosted PI, 23% were on a
boosted-PI, and 27% were on a NNRTI. During the fol-
low-up period, patients were on HAART an average of
93% of the time.
VL, CD4 and Clinical Outcomes
The percentage of patients with VS (Table 2) was higher
in the LHE compared to the EHE throughout follow-up
(p < 0.001). One year after HAART initiation, 57% and
81% of patients with available viral loads had VS in the
EHE and LHE, respectively. Restricting analyses to active
duty patients, these percentages were slightly higher (64%
and 84%, respectively). The percentage of patients with
VS at 5 years was 59% and 85%, and at 8 years was 65%
and 82% for the EHE and LHE, respectively. Analyses
restricted to active duty patients showed nearly identical
results at these time points. The cumulative percentage of
patients who achieved an undetectable viral load ever
within 5 years after HAART initiation was 93.2%. In a
subset of patients where self-reported adherence was
available within 15 months of HAART start (n = 133),
over 94% reported ≥ 90% adherence. A cross-sectional
assessment of adherence for all patients in the cohort on
HAART (n = 1050) demonstrated over 90% reporting ≥
90% adherence.
There were also significant differences between the eras
in the percentage of patients who were always sup-
pressed, never suppressed or had at least one virologic
rebound event throughout the study period. At 1 year,
19% of patients in the LHE experienced VF (versus 43%
EHE). For this same era at 5 and 8 years, there were 34%
and 50% of LHE patients (versus 61% and 68% EHE),
respectively. Similarly, the degree of immune reconstitu-
tion was greater in the LHE, despite similar CD4 levels at
HAART start. In the first year, 52% of patients from the
LHE had achieved a 50% gain in CD4 count. This
increased to 63% of patients at 5 years.
The rate of AIDS events and deaths were lower in the
LHE compared to the EHE. At 1 year, the AIDS event rate
(Figure 2) was 4.7% for patients in the EHE and 2.0% for
patients in the LHE; the mortality rates were 1.0% and
0.3%, respectively. These rates remained low and the dif-
ferences persisted throughout the study period.
Predictors of Response to HAART
In a multivariate model (T able 3) stratified by HAART
initiation era and MTF that included age, gender, ethnic-
ity, active duty status, military rank, CD4 count, VL,
duration of HIV infection, prior ARV use, initial HAART
regimen, STIs, hepatitis B and C co-infection and Hgb,
the factors significantly (p < 0.05) associated with VF
were younger age at HAART initiation, African-Ameri-
can ethnicity, higher VL at HAART initiation, prior use of
ARVs, and no prior history of STI. The factors signifi-
cantly associated with achieving a CD4 cell gain of at least
50% were being on active duty at HAAR T start, lower
CD4 count at HAART start, shorter duration of HIV
infection, and no prior ARV use. Ethnicity nearly reached
significance for this outcome. Risk factors associated with
AIDS events after HAART were younger age, male gen-
der, lower CD4 count, and prior AIDS events. Non-active
duty status and duration of HIV infection showed a trend
towards significance. Factors associated with higher mor-
tality included non-active duty status, lower CD4 count at
HAART initiation, higher VL at HAART initiation, HCV
co-infection, and lower Hgb. No difference was seen
when comparing PI to NNRTI use as the first regimen.
Although patients on active duty had better clinical and
immunologic outcomes as well as a higher likelihood of
VS (data not shown), no difference was found with time
to VF.Marconi et al. AIDS Research and Therapy 2010, 7:14
http://www.aidsrestherapy.com/content/7/1/14
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Age at HIV Diagnosis, years 30.1 ± 8.1 29.8 ± 7.9 30.8 ± 8.6 0.007
Age at HAART initiation, years 34.7 ± 8.6 35.0 ± 8.2 34.1 ± 9.5 0.025
Female 221 (9.5%) 169 (10.4%) 52 (7.5%) 0.029
Race/ethnicity 0.188
European American 1024 (44.0%) 730 (44.8%) 294 (42.2%)
African American 1021 (43.9%) 717 (44.0%) 304 (43.7%)
Hispanic 194 (8.3%) 130 (8.0%) 64 (9.2%)
Other 88 (3.8%) 54 (3.3%) 34 (4.9%)
Rank of Officer/Warrant at study enrollment 213 (9.9%) 143 (9.4%) 70 (10.1%) 0.606
Active Duty at HAART initiation 1293 (55.6%) 773 (47.4%) 520 (74.7%) <0.001
Medical History (prior to HAART Initiation)
Year of HIV Diagnosis 1994 ± 5.9 1992 ± 4.2 2000 ± 5.1 <0.001
HIV Diagnosis to HAART initiation, months 44.2 (5.7 - 95.2) 60.9 (16.9 - 103.8) 10.1 (2.0 - 45.5) <0.001
Nadir CD4+ to HAART initiation, months 3.3 (0.4 - 16.3) 6.5 (0.7 - 19.4) 0.8 (0.2 - 3.7) <0.001
Seroconverters (SC)a 1691 (72.7%) 1106 (67.8%) 585 (84.1%) <0.001
Estimated date of SC to HIV Diagnosis, months 8.1 (5.0 - 13.7) 8.4 (5.3 - 14.4) 7.4 (5.0 - 13.7) 0.010
Viral Load at HAART initiation, log10 copies/mL 4.3 ± 1.0 4.3 ± 1.0 4.4 ± 0.9 <0.001
CD4+ at HIV Diagnosis, cells/mL 499.7 ± 248.0 524.0 ± 252.1 448.0 ± 231.0 <0.001
CD4+ nadir, cells/mL 283.2 ± 174.0 276.4 ± 183.3 299.6 ± 148.1 0.005
CD4+ at HAART Initiation, cells/mL 342.8 ± 211.6 341.0 ± 223.4 346.6 ± 184.8 0.590
<200 459 (24.4%) 357 (28.0%) 102 (16.7%) <0.001
200-349 581 (30.8%) 331 (26.0%) 250 (40.9%)
350+ 845 (44.8%) 586 (46.0%) 259 (42.4%)
Prior AIDS-Defining Event 277 (11.9%) 231 (14.2%) 46 (6.6%) <0.001
Chronic Hepatitis B co-infection 128 (6.1%) 110 (7.4%) 18 (2.9%) <0.001
Hepatitis C co-infection 121 (6.1%) 99 (7.1%) 22 (3.6%) 0.002
Prior Sexually Transmitted Infections (STI) 1058 (45.5%) 839 (51.4%) 219 (31.5%) <0.001
ARV Use (mono- or dual-therapy) 1224 (52.6%) 1121 (68.7%) 103 (14.8%) <0.001
Hemoglobin, g/dL 14.1 ± 1.6 13.9 ± 1.6 14.4 ± 1.4 <0.001
ALT, μ/L 47.1 ± 53.7 48.2 ± 52.9 45.1 ± 55.2 0.336
Creatinine, mg/dL 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 <0.001
Initial HAART Regimen
Unboosted PI 1320 (56.7%) 1261 (77.3%) 59 (8.5%) <0.001
Boosted PI 205 (8.8%) 121 (7.4%) 84 (12.1%)
NNRTI 622 (26.7%) 169 (10.4%) 453 (65.1%)
PI + NNRTI + NRTI 86 (3.7%) 71 (4.4%) 15 (2.2%)
3 NRTI 94 (4.0%) 9 (0.6%) 85 (12.2%)
Median (IQR) is presented for duration factors given in months
a Percentage of patients who are known seroconverters
b Late versus Early HAART initiation eraMarconi et al. AIDS Research and Therapy 2010, 7:14
http://www.aidsrestherapy.com/content/7/1/14
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Discussion
In this study, we describe the clinical characteristics and
response to HAAR T among HIV -infected military per-
sonnel and beneficiaries initiating treatment over the
course of twelve years (1996-2007) with an average fol-
low-up of over 6 years. The NHS is conducted within the
military medical system allowing for an evaluation of
HAART response in a U.S. clinical setting with free and
open access to healthcare and medications.
After stratifying patients into two HAART initiation
eras, 1996-2000 (EHE) and 2000 onward (LHE), it was
evident that these eras differed significantly for several
reasons. First, the large majority of patients starting treat-
ment in the EHE had prior exposure to suboptimal ther-
apy which has been shown to compromise the response
to HAART [19-21]. Secondly, more potent regimens were
available in the LHE. Additionally, more patients in the
EHE had a prior AIDS-defining illness likely impacting
response [22,23]. Furthermore, those who survived the
pre-HAART era long enough to initiate HAART may
have intrinsic host factors which could impact outcomes
[24]. Finally, there were significant differences in the tim-
ing of HAART initiation between both eras (duration of
HIV diagnosis to HAART initiation and baseline CD4
count). This likely reflects differences in treatment guide-
line recommendations that were followed in each era and
the fact that many patients starting HAART in the EHE
became infected well before the availability of HAART .
Despite the challenges experienced by participants initi-
ating in the EHE, the percent virologically suppressed
was around 60% throughout the duration of follow up.
For the LHE patients in this cohort, the virologic and
immunologic responses were similar to those reported by
randomized clinical trials using a regimen containing
either efavirenz or a boosted-PI. A meta-analysis of 20
clinical trials by Gupta et al. described a VS rate of 76%
and CD4 change of 176 cells/mL at 48 weeks [25]. The
rates we observed were equivalent or slightly higher than
these and were sustained for more than 5 years. Limited
population and cohort studies in the U.S. have shown
variable VS rates at 3 to 8 months of 50-85% and rebound
at 3 years of 20-50% [26,27]. Outside the U.S., several
cohorts with universal access to healthcare have demon-
strated a remarkable response to HAART when com-
pared to cohorts with similar demographics in the
U.S.[3,28-31]. The Swiss HIV Cohort Study reported an
overall ITT VS rate of 89% and a CD4 increase of 177
cells/mL at 12 months after HAART initiation for ARV
naïve patients during this same LHE [32]. In this same
analysis, the percentage of patients having a change or
discontinuation within the first year of ART for any rea-
son was 44.3-48.8% (varying by era) which is comparable
to patients in the NHS.
Although there are drug assistance programs in the U.S.
for eligible individuals with HIV/AIDS, the delay before
medical care becomes available can postpone HAART
initiation, and even the minimal associated costs can be a
significant barrier for some patients [33,34]. Co-pay-
ments and fees can reduce adherence and have been
shown to increase mortality [35-37]. It is important to
note, however, that universal access to care and free med-
ications are insufficient to ensure that all patients will
achieve treatment success. Joy et al. described a popula-
tion in Vancouver, Canada that has open access to health-
care but found that poverty, unemployment and a lack of
post-secondary education impacted on survival in the
HAART era [38-40].
This cohort provided an opportunity to examine the
relationship between demographic and clinical factors
with outcomes after HAART in a clinical setting that
minimized confounding related to access to care and
IDU. Previously, we and others have shown associations
between both age at HAART initiation [41] and ethnicity
[17,42,43] with treatment response. Concordant with
other studies, viral load was a predictor of VF and mortal-
ity and CD4 count was a predictor of immune reconstitu-
tion, AIDS events, and mortality [44-46]. The CD4
Figure 1 HAART usage in the Natural History Study. (A) Distribu-
tion of prior ARV use and first regimen type by year of HAART initiation 
with duration of HIV infection prior to HAART start for seroconverters. 
(B) Therapy changes over time. The declining percentage of patients 
remaining on the first HAART regimen results from complete discon-
tinuation of or changes in therapy.
A.
B.Marconi et al. AIDS Research and Therapy 2010, 7:14
http://www.aidsrestherapy.com/content/7/1/14
Page 6 of 10
recovery was greatest for those with lower baseline CD4
counts similar to findings by Hunt et al. [47] which likely
reflects the endpoint used in this analysis (50% increase).
We also showed an association between the duration of
HIV infection and CD4 reconstitution [48] in addition to
increased AIDS events despite a lack of evidence for these
findings in a previous prospective study [49]. Although
conflicting findings abound in the literature with respect
to gender differences in HAART response [50], in the
present study, women had a longer time to AIDS as com-
pared to men (consistent with several similar reports [51-
54]). Surprisingly, among all subjects the initial regimen
type was not found to be a significant predictor of VF
[55]. Although this analysis did not distinguish among the
NNRTIs or boosted-PIs from unboosted-PIs, the era
stratification accounted for differences in drug potency.
Interestingly in our study, patients with a prior STI had a
lower rate of VF. This is in contrast to studies showing a
higher incidence of STIs being associated with non-
adherence [56-58] or a negative impact on VL and CD4
count likely via increased immune activation [59].
Active duty status was associated with improved sur-
vival, immune reconstitution and a lower rate of AIDS-
defining events. Although a distinctive factor in our
cohort, important implications related to adherence and
general health can be proposed as to why individuals on
active duty had improved outcomes; some of which could
be translated to other settings. Factors that might
improve an active duty member's medication adherence
include: (1) better access to ARVs, (2) closer clinical mon-
itoring, and (3) a more disciplined and regimented envi-
ronment. Although all participants in this cohort study
do have free access to the DoD healthcare system, retirees
can live further from network facilities and can choose
private insurance resulting in copayments for ARVs. Fur-
thermore, active duty personnel may be more closely
monitored as they are required by their supervisors to
s e e k  m e d i c a l  c a r e  o n  a  r e g u l a r  b a s i s .  A s  e v i d e n c e ,
research study visit attendance has been shown to be sig-
nificantly greater for active duty vs. others [17]. General
health may be better among active duty members
because of physical fitness requirements, lower rates of
substance abuse, and a cultural awareness of the benefits
Table 2: Virologic and Immunologic Outcomes for patients initiating HAART using an Intention to Treat Analysis.
Outcome 1 year 5 years 8 years
HAART Era Total Early Late Total Early Late Total Early Late
Median (IQR) # of viral 
loads available per patient
4 (3-6) 4 (3-6) 5 (3-6) 17 (12-23) 18 (12-24) 15 (12-19) 26 (18-35) 26 (18-35) 20 (15-27)
Virologic Suppression (n) 1759 1216 543 1063 868 195 735 707 28
Suppresseda 1135 (64.5) 693 (57.0)g 442 (81.4) 674 (63.4) 508 (58.5)g 166 (85.1) 487 (66.3) 464 (65.6) 23 (82.1)
Always Suppressedb 864 (49.1) 478 (39.3)g 386 (71.1) 244 (23.0) 172 (19.8)g 72 (36.9) 112 (15.2) 104 (14.7) 8 (28.6)
Ever Suppressedc 1391 (79.1) 890 (73.2) 501 (92.3) 991 (93.2) 800 (92.2) 191 (97.9) 707 (96.2) 680 (96.2) 27 (96.4)
Virologic Failured 629 (35.8) 525 (43.2)g 104 (19.2) 594 (55.9) 527 (60.7)g 67 (34.4) 496 (67.5) 482 (68.2)g 14 (50. 0)
Never Suppressede 368 (20.9) 326 (26.8)g 42 (7.7) 72 (6.8) 68 (7.8)g 4 (2.1) 28 (3.8) 27 (3.8) 1 (3.6)
Reboundf 261 (14.8) 199 (16.4)g 62 (11.4) 522 (49.1) 459 (52.9)g 63 (32.3) 468 (63.7) 455 (64.4) 13 (46.4)
Mean CD4, cells/mL 488 ± 267 469 ± 268 530 ± 262 571 ± 306 562 ± 305 611 ± 307 556 ± 306 552 ± 301 657 ± 398
CD4 Change 143 ± 180 126 ± 171g 179 ± 193 220 ± 271 214 ± 270 247 ± 278 209 ± 288 206 ± 284 263 ± 362
CD4 Increase ≥ 30% 880 (60.0) 564 (56.9) 316 (66.5) 583 (66.9) 461 (65.3) 122 (73.5) 381 (62.5) 365 (62.6) 16 (59.3)
CD4 Increase ≥ 50% 665 (45.4) 418 (42.2) 247 (52.0) 489 (56.1) 385 (54.5) 104 (62.7) 331 (54.3) 318 (54.5) 13 (48.1)
Patients with missing lab values were excluded on that date
aNumber (%) of patients at the given time point who have one undetectable viral load
bNumber (%) of patients suppressed at 6-months and then at all visits through indicated time point
cNumber (%) of patients having an undetectable viral load at least once through indicated time point
dNumber (%) of patients at the given time point who have either had at least one episode of rebound or never suppressed
eNumber (%) of patients never having an undetectable viral load
fNumber (%) of patients ever having a rebound event (undetectable, then detectable + detectable)
gSignificant difference comparing early versus late era (p < 0.05)Marconi et al. AIDS Research and Therapy 2010, 7:14
http://www.aidsrestherapy.com/content/7/1/14
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Figure 2 KM curves for cumulative clinical outcomes for patients after HAART initiation stratified by HAART Era. (A) First AIDS event (B) Mor-
tality.
A.
B.Marconi et al. AIDS Research and Therapy 2010, 7:14
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of health and nutrition [4,29,60]. Additional factors such
as stable employment and guaranteed housing may also
contribute to better outcomes. Finally, the goal of remain-
ing on active duty itself is an incentive to stay healthy.
HIV-infected military personnel can remain on active
duty and continue working, but the development of an
AIDS-defining illness can lead to medical separation with
retention of health benefits. Although the MV analysis
adjusted for several clinical factors such as previous AIDS
event, it is possible that non-active duty status is a marker
for poorer health. This is substantiated by the fact that
28% of non-active duty patients were retired for medical
reasons prior to the start of HAART.
One limitation of this study is that medication adher-
ence data were unavailable for most patients (adherence
questionnaires were added to the data collection in 2006).
The relative impact of HIV drug resistance was also not
a s s e s s e d  i n  t h i s  s t u d y .  F i n a l l y ,  a  d i s a d v a n t a g e  o f  a n y
cohort study is that these results cannot be readily
extrapolated to other clinical settings where rates of IDU,
demographic characteristics, and access to healthcare dif-
fer. However, this cohort does provide an opportunity to
observe sustainable treatment success after early HAART
initiation under these conditions.
Conclusions
In summary, we find rates of VS and CD4 reconstitution
to be high and clinical events to be low for DoD benefi-
ciaries receiving treatment for HIV. These rates approach
those reported in clinical trials. Active duty personnel
have better immunologic and clinical outcomes but
equivalent rates of VF to other beneficiaries. These find-
i n g s  s u p p o r t  t h e  n o t i o n  t h a t  f r e e  a n d  o p e n  a c c e s s  t o
healthcare provides a favorable environment for optimiz-
ing HIV treatment outcomes.
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